Skip to content
Screener

Madrigal Pharmaceuticals, Inc. MDGL Q2 2026 earnings

Reported July 30, 2026 · Before market open

Revenue$364.3MBeat by $12.2M
EPS-$1.99Beat by $0.69
Revenue estimate$352.1M
EPS estimate-$2.68

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$404.2M
EPS estimate-$0.86

Financials

Q2 2026

Income statement

See full
Revenue$364.3M+71.2%
Operating income-$56.3M-19.3%
Net income-$57.9M-37.0%
EPS (diluted)-$1.99-4.7%

Balance sheet

See full
Cash & equivalents$292.9M+53.2%
Total debt$377.9M+179%
Total equity$523.7M-24.7%
Total assets$1.2B+22.6%

Cash flow

See full
CapEx$4.3M—

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$12.09B+31.4%
Enterprise value$12.17B+33.1%
P/S9.4×-8.4×

Profitability

See full
Operating margin-25.1%-9.2pp
Net margin-25.3%-8.8pp

Returns & leverage

See full
Return on equity-53.3%+47.0pp
Debt / equity0.7×+0.5×
Current ratio3.2×-1.9×

Segments

By segment

See full
Reportable Segment$364.3M+71.2%

FAQ

When did Madrigal Pharmaceuticals, Inc. report Q2 2026 earnings?
Madrigal Pharmaceuticals, Inc. (MDGL) reported Q2 2026 earnings on July 30, 2026 before market open.
What were Madrigal Pharmaceuticals, Inc.'s Q2 2026 revenue and EPS?
Madrigal Pharmaceuticals, Inc. reported revenue of $364.3M and eps of $-1.99 for Q2 2026.
Did Madrigal Pharmaceuticals, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $352.1M by $12.2M. EPS beat the consensus estimate of $-2.68 by $0.69.
How did Madrigal Pharmaceuticals, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 71.2% from $212.8M a year earlier and eps declined 4.7% from $-1.90.
Where can I find Madrigal Pharmaceuticals, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-050775) and the 10-Q periodic report (0001628280-26-050845) directly on SEC EDGAR. The filing index links above go to sec.gov.